Journal of Cancer 2022

4 papers
The 2022 edition of the Journal of Cancer emphasized molecular signaling hierarchies and post-transcriptional regulation mechanisms. Research themes included the role of MicroRNA-30a-3p as a tumor suppressor in hepatocellular carcinoma and the modulation of the Bcl-2 family ratio to control cell fate. Beyond molecular biology, the journal addressed visual data integrity in scientific publishing, highlighting a focus on research transparency and quality standards. Clinical studies from this year explored diagnostic and prognostic methodologies, such as the evaluation of the PCC staging system for surgical resectability. Other work included the development of a classifier using platelet features to differentiate between malignant and benign pulmonary nodules, as well as investigations into the prognostic impact of tumor budding in intrahepatic cholangiocellular carcinoma. Prolific contributors during this period included researchers such as Chuang Peng, Kashif Shakoor, and Sulai Liu. These publications reflect a trend toward integrating molecular insights with practical clinical assessments to improve cancer diagnosis and prognosis.

Top Research Directions

The 5 research directions with Journal of Cancer 2022 papers, ranked by paper count, next to 2021. Share is the fraction of the edition’s papers in the direction.

#Direction20222021Share 2022Share 20212021 rank
1Multi-Metric Evaluation of Clinical Prediction Models1025.0%0.0%—
2Optimizing the Extent of Surgical Resection1025.0%0.0%—
3Overcoming Diagnostic Subjectivity with Computational Pathology1125.0%10.0%23
4Quantifying Clinical Utility Through Risk Reclassification Metrics1025.0%0.0%—
5The Mechanics of Gradient Boosting Decision Trees1025.0%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Journal of Cancer 2022 papers: a paper credits every institution named in its affiliations, once. 14 institutions share 4 credited papers.

#InstitutionPapersShare20212021 rank
100pvqk557 125.0%0—
201qh26a66 125.0%0—
3029wq9x81 125.0%0—
403wwr4r78 125.0%0—
5Chengdu University of Traditional Chinese Medicine 125.0%0—
6Chiang Mai University 125.0%0—
7German Cancer Research Center 125.0%0—
8Hunan Normal University 125.0%0—
9Memorial Sloan Kettering Cancer Center 125.0%0—
10Sichuan University 125.0%0—
11Southern Medical University 125.0%19
12University Medical Center Freiburg 125.0%0—
13University of Electronic Science and Technology of China 125.0%0—
14University of Freiburg 125.0%0—

Download all institutions as CSV

About this data

Papers. Journal of Cancer 2022 lists 4 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2021 use shares, since the edition went from 10 to 4 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 4 of 4 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-17 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Cancer 2022”, https://lacuna.tiptreesystems.com/venue/journal-of-cancer/2022.

Top Authors

AuthorPapers
Lin Yuanbo Wu1

Impactful Papers

Papers from Journal of Cancer 2022 that shaped research clusters.

Influential

Papers

Title
A new classifier constructed with platelet features for malignant and benign pulmonary nodules based on prospective real-world data
MicroRNA-30a-3p acts as a tumor suppressor in MHCC-97H hepatocellular carcinoma cells by targeting COX-2: Erratum
Prognostic Impact of Tumor Budding in Intrahepatic Cholangiocellular Carcinoma
The pros and cons of the PCC staging system to guide surgical resectability and prognosis